CAPR Capricor Therapeutics Inc
Price (delayed)
$9.74
Market cap
$444.89M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.15
Enterprise value
$435.05M
Capricor Therapeutics, Inc., is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead
Highlights
CAPR's equity has soared by 113% since the previous quarter
CAPR's quick ratio has soared by 85% QoQ
Capricor Therapeutics's net income has shrunk by 82% YoY and by 19% QoQ
The EPS has declined by 39% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of CAPR
Market
Valuations
Earnings
Shares outstanding
45.68M
Market cap
$444.89M
Enterprise value
$435.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.04
Price to sales (P/S)
15.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.53
Revenue
$22.27M
Gross profit
$22.27M
Operating income
-$42.56M
Net income
-$40.47M
EBIT
-$40.47M
EBITDA
-$39.04M
Free cash flow
-$41.53M
Per share
Balance sheet
Liquidity
EPS
-$1.15
EPS diluted
-$1.15
Free cash flow per share
-$1.18
Book value per share
$3.2
Revenue per share
$0.63
TBVPS
$4.84
Total assets
$170.48M
Total liabilities
$25.02M
Debt
$1.45M
Equity
$145.46M
Working capital
$142.36M
Debt to equity
0.01
Current ratio
7.77
Quick ratio
7.7
Net debt/EBITDA
0.25
Margins
Efficiency
Dividend
EBITDA margin
-175.3%
Gross margin
100%
Net margin
-181.7%
Operating margin
-191.1%
Return on assets
-46.1%
Return on equity
-66.4%
Return on invested capital
-94.5%
Return on capital employed
-27.1%
Return on sales
-181.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CAPR stock price
How has the Capricor Therapeutics stock price performed over time
Intraday
2.8%
1 week
-26.1%
1 month
-36.67%
1 year
41.36%
YTD
-29.42%
QTD
2.63%
Financial performance
How have Capricor Therapeutics's revenue and profit performed over time
Revenue
$22.27M
Gross profit
$22.27M
Operating income
-$42.56M
Net income
-$40.47M
Gross margin
100%
Net margin
-181.7%
The net margin has dropped by 105% year-on-year and by 24% since the previous quarter
The company's operating margin has shrunk by 100% YoY and by 23% QoQ
Capricor Therapeutics's net income has shrunk by 82% YoY and by 19% QoQ
The operating income has dropped by 77% year-on-year and by 18% since the previous quarter
Growth
What is Capricor Therapeutics's growth rate over time
Valuation
What is Capricor Therapeutics stock price valuation
P/E
N/A
P/B
3.04
P/S
15.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19.53
The EPS has declined by 39% year-on-year and by 13% since the previous quarter
CAPR's equity has soared by 113% since the previous quarter
CAPR's P/B is 67% lower than its last 4 quarters average of 9.1 and 64% lower than its 5-year quarterly average of 8.3
The price to sales (P/S) is 90% less than the 5-year quarterly average of 151.3 but 5% more than the last 4 quarters average of 14.2
CAPR's revenue is down by 12% year-on-year and by 4.1% since the previous quarter
Efficiency
How efficient is Capricor Therapeutics business performance
The ROS has dropped by 105% year-on-year and by 24% since the previous quarter
The ROE has soared by 78% YoY and by 41% QoQ
CAPR's ROIC has soared by 74% YoY and by 68% from the previous quarter
The ROA has increased by 19% QoQ
Dividends
What is CAPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CAPR.
Financial health
How did Capricor Therapeutics financials performed over time
Capricor Therapeutics's total assets has surged by 190% YoY and by 83% QoQ
CAPR's quick ratio has soared by 85% QoQ
The debt is 99% smaller than the equity
CAPR's equity has soared by 113% since the previous quarter
The debt to equity has plunged by 90% YoY and by 50% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.